Can Vimian Group (OM:VIMIAN) Justify Its Price On Higher Third Quarter Sales And Net Income?

Vimian Group (OM:VIMIAN) is back in focus after reporting third quarter 2026 results, with higher sales and net income for both the quarter and the nine month period compared with last year.

Against that backdrop, Vimian Group’s share price has climbed to SEK40.9, with a 30-day share price return of 14.89% and a 33.31% year-to-date share price gain. The 1-year total shareholder return of 28.78% and 3-year total shareholder return of 78.23% point to momentum that has been building rather than fading.

Scan other animal health and medtech momentum stories in our hand picked 612 high quality undiscovered gems that share some of the same quality markers investors are watching in Vimian Group today.

After a sharp move on solid quarterly numbers, the real tension for Vimian Group now is simple. Do you pay up at SEK40.9 or wait and hope the valuation offers a cleaner entry later?

Most Popular Narrative: 11.5% Overvalued

Vimian Group closed at SEK40.9, while the most followed narrative pegs fair value closer to SEK36.68. As a result, the current price sits ahead of that storyline and puts more pressure on execution to match expectations.

Expansion in high-margin, niche segments such as veterinary dental products and specialty pharmaceuticals, now supported by 75 product launches over 12 months, more than 60 products in the pipeline, and a new biologics focused R&D hub in France, points to continued mix shift toward higher value portfolios that can support revenue growth and adjusted EBITA margins.

See why 2 investors see Vimian Group as 12% overvalued.

Result: Fair Value of SEK36.68 (OVERVALUED)

Still, the story can change quickly if working capital continues to absorb cash or if central costs remain close to €3.0 million each quarter.

Find out about the key risks to this Vimian Group narrative.

Another View: Multiples Put Vimian Group In Context

The most followed fair value story says Vimian Group looks 11.5% overvalued at SEK40.9, yet the P/E picture is less one sided. The stock trades on 49.8x earnings, lower than the peer average at 78.1x, but higher than the fair ratio of 38.3x that the market could move toward. That mix of relative discount and fair ratio premium leaves you weighing upside against valuation risk. Where does that balance sit for you now?

For a closer look at what the numbers imply if the market leans toward the fair ratio instead of current trading levels, See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Sentiment around Vimian Group is leaning positive, so move quickly, test the numbers yourself, and then weigh up the balance of risks and upside. To see what optimism is already built into the story, read through the 3 key rewards.

Looking for more Vimian Group style investment ideas?

If Vimian Group has you thinking harder about quality and risk, do not stop here. Use the Simply Wall St screener to surface more focused opportunities fast.

• Target resilience by filtering for steady balance sheets and solid fundamentals through our list of solid balance sheet and fundamentals (207 results).
• Hunt for quality that the market may be pricing too cautiously with the 194 high quality undervalued stocks.
• Explore income-focused opportunities that are currently available by scanning the 229 dividend fortresses.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com